Accelerated phase or blast crisis However, the two are survival rate after five years with second-line treatment with dasatinib or nilotinib as allogeneic SCT in chronic phase, but not in the accelerated phase or blast crisis after failure of imatinib compared. The processing aussagekr Ftige Tipifarnib R115777 comparisons between long-term survival of allogeneic SCT and not online a second transplant Ans PageSever after imatinib failure are not available at the moment. Treatment decisions in individual patients failing or suboptimal response to imatinib should take the right patients to consider the individual situation and risk factors. Therefore Kantarjian et al developed a new risk score in this group of patients, including normal splenomegaly and h Dermatological failure as independent-Dependent prognostic factors.
Interestingly, patients with target-independent-Dependent mechanisms of resistance to imatinib probably not get a benefi supported Abl kinase inhibitors specifically c, and today, these A-674563 patients should proceed with allogeneic SCT, if possible m. In a patient with signs appear, the standard treatment is still imatinib 400 mg, but what doctors should be alert that the patient is entitled to alternative therapeutic Ans PageSever shaded above. monitoring of blood concentrations of imatinib is not routinely recommended strength, but it may be desirable in case of failure, and in patients receiving drugs that st with imatinib metabolism Ren by cytochrome P450 or drugs it needs experienced serious adverse events f llig.
Patients with blast crisis dd if diagnosis imatinib or other tyrosine kinase inhibitor was followed suggested allogeneic SCT. Patients who do not respond to imatinib or an alternative approach to targeted appropriate induction chemotherapy k Nnte be used to induce remission before the transplant. Since remission with imatinib in CML accelerated phase achieved clearly l singer as prone in blast crisis, an L Ngere study of imatinib in these patients m Possible. However, if possible m, Allogeneic stem cell transplantation should be discussed and planned in such cases F. Findings led to the amplifier Ndnis the molecular mechanisms underlying CML and erm glichte The development of effective targeted therapies.
Imatinib is a breakthrough not only for the treatment of CML patients, but also for the fa There, the amplifier Ndnis for targeted therapies for the treatment of other b Sartigen diseases advance. In addition, deciphering the molecular mechanisms of imatinib resistance to the rapid development of an effective second-line drugs for the treatment of patients with imatinib out. Treatment of CML has not been reached, blocking Bcr Abl kinase. It remains the big challenge for e full gowns’s full elimination of the clone of tumor cells in patients with CML. Been shown to inhibit the large number of potential drugs or t Th Bcr Abl positive cells test innovative hypotheses in clinical trials in order to achieve this goal Nally fi. Prostate cancer is a leading cause of cancer death in the United States among men. To induce the development of chemotherapeutic agents, the apoptosis of tumor cells with a lower toxicity t In the patient is currently